|
|
News for Healthier Living
Injectable Treprostinil Depot Offers Multiday Control of Pulmonary Hypertension
A research team has developed a long-acting injectable treprostinil depot that forms a drug-releasing gel inside the body, providing sustained pulmonary vasodilation for three to four days after a single intramuscular injection in rats with pulmonary arterial hypertension (PAH). The formulation prolonged drug residence, stabilized plasma concentrations, reduced pulmonary arterial pressure, and limited pulmonary vascular and right ventricular remodeling. It also showed favorable biocompatibility, with mild injection-site inflammation resolving within one week. If validated in further preclinical and clinical studies, this pump-free delivery strategy could reduce dosing frequency, simplify treprostinil administration, improve treatment adherence, and enhance quality of life for people living with PAH.
August 31, 2026
September 1 2026August 31 2026August 30 2026August 29 2026August 28 2026August 27 2026August 26 2026August 25 2026August 24 2026August 21 2026August 20 2026August 19 2026August 18 2026
|
|
|
|
|